About 6.4M results
Enhertu Approved for Any HER2-Positive Solid Cancer - NCI
Enhertu Effective in HER2-Positive Metastatic Breast Cancer
ENHERTU® Showed Substantial Clinical Activity in Patients with …
Enhertu demonstrated clinically meaningful survival across …
Enhertu demonstrated a median progression-free survival of 13.2 …
Enhertu achieved statistically significant overall survival, reducing ...
FDA approves new treatment option for patients with HER2 …
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the …
ENHERTU® Granted Priority Review in the U.S. for Patients with ...
Enhertu Breast Cancer Drug Results in ‘Unheard-of’ Survival Rates